Skip to main content
. 2021 Feb 15;81(2):283–289. doi: 10.1007/s40265-020-01464-z

graphic file with name 40265_2020_1464_Figa_HTML.jpg

Key milestones in the development of lonafarnib for the treatment of progeria and progeroid laminopathies. EAP expanded access program, MAA marketing authorization application